What’s more, ERBB4 and TP53 deficiencies could moderate the infiltrating immune cells and augment tumor immunogenicity by activating the process of antigen presentation and anticancer cellular immunity in patients with NSCLC. This evidence concerns the gene TP53 and non-small cell lung carcinoma.